On November 15, 2021 Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, reported the publication of a scientific paper in the peer-reviewed international scientific journal, ACS Pharmacology & Translational Science (Press release, Oryzon, NOV 15, 2021, View Source [SID1234595630]). The article reports a comprehensive comparison of iadademstat, the first LSD1 inhibitor to be developed in the clinic, with most of the LSD1 inhibitors in development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The manuscript, entitled "Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology", compares iadademstat with four LSD1 inhibitors in clinical development in oncology and with five commonly used compounds used in the academia as tool LSD1 inhibitors. Results show that iadademstat is consistently the most active compound across diverse cancer cell lines, that its capability to bind the target is superior, specially at low concentrations, and that the disruption of the transcriptional complexes implicated in the oncogenic programs is more efficacious in the case of iadademstat.
Dr. Jordi Xaus, Oryzon’s CSO, commented: "This set of head-to-head controlled comparisons have shown that iadademstat is clearly the most potent and selective LSD1 inhibitor among all tested clinical molecules. This correlates with the need for lower doses in the clinic, which greatly reduces the potential for idiosyncratic toxicity. A relevant result in this study is that at lower concentrations iadademstat is, by far, the most efficacious in binding LSD1. This may have clinical relevance in solid, dense and poorly vascularized tumors, where the access of drugs to tumoral cells is often an issue".
The paper has been published in the journal ACS Pharmacology & Translational Science as part of the special issue Epigenetics 2022 and is already accessible on-line. The paper can be accessed here: View Source